LONDON, May 30, 2017 /PRNewswire/ -- Transcatheter aortic valve implantation (TAVI) is used for the replacement of aortic valves through vessels or minimally-invasive transapical routes in patients suffering from aortic stenosis and for whom open heart surgery is contraindicated or could lead to high mortality risk.
Download the full report: https://www.reportbuyer.com/product/4890876/TAVI is a well-established treatment option in Europe. The report explores reimbursement situations for TAVI using both transluminal and transapical access in 11 European countries: Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. The report also includes information about reimbursement systems for medical devices, procedure coding for TAVI, diagnosis coding, payment mechanisms, reimbursement tariffs, policy considerations by payers and policy-makers as well as restrictions on indications or scenarios for use of TAVI. Reimbursement tariffs are provided for the procedure with and without peri-operative complications, including stroke.Information for this research was obtained from publicly available sources provided by national authorities who maintain procedural classifications, develop national payment systems, and determine coverage policies in health care (including health technology assessment bodies). No payer interviews were performed with the exception of requests to authorities when clarifications about procedure coding or reimbursement status were required. TAVI is well established technology with reimbursement available in all studied European geographies. The main payment models are diagnosis-related group (DRG) for entire hospitalization, add-on reimbursement (England, France, Italy in some regions) and fee for procedure and material (Belgium). All geographies, but Italy, have specific procedure codes for TAVI. Brand-specific reimbursement is only available in Belgium and France, while in other countries reimbursement is established for the class of devices.Reimbursement differs for different types of access for procedure only in France, Germany and Switzerland. In Germany and Switzerland procedure with transapical access has higher reimbursement.Complications or stroke specifically do not impact allocation to DRG and reimbursement level in any of studied countries, with exception of France.Download the full report: https://www.reportbuyer.com/product/4890876/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected]
Tel: +44 208 816 85 48 Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/transcatheter-aortic-valve-implantation-european-reimbursement-report-300465553.html
SOURCE ReportBuyer
